Clinical Trials and Product Development - BiondVax Pharmaceuticals has executed eight clinical trials, including a phase 3 trial with 12,400 participants for its previous lead drug candidate, M-001[68] - The company has developed a pipeline of diversified products based on its innovative nanosized antibody (NanoAb) platform, which is expected to provide competitive advantages in treatment efficacy and delivery methods[71] - BiondVax signed a definitive exclusive License Agreement with the Max Planck Society and University Medical Center Göttingen for the development of NanoAbs for COVID-19, which includes upfront payments and royalties based on sales[69] - The company anticipates that its NanoAbs can be developed and brought to clinical trials at a lower cost and faster timeline compared to traditional monoclonal antibodies[73] - BiondVax's NanoAbs demonstrate binding affinity and neutralization at doses 100 to 1000 times lower than other antibodies, potentially leading to faster medical efficacy[72] - The company aims to leverage its unique NanoAb attributes to address large and underserved medical needs in various therapeutic areas, including psoriasis and asthma[71] Manufacturing and Financial Support - BiondVax's GMP biologics manufacturing facility in Jerusalem is capable of producing clinical-grade NanoAbs, allowing for direct control over production and reduced reliance on third-party manufacturers[76] - The company has borrowed €24 million under a finance contract with the European Investment Bank to support the development of its previous drug candidate and manufacturing facility[77] - The company has received $5.8 million in IIA grants and €24 million ($25.6 million) in EIB loans since its inception[87] Financial Performance and Projections - For the three months ended March 31, 2023, the net loss was $3.5 million, compared to a net loss of $2.47 million for the same period in 2022, reflecting an increase in operating expenses[89] - Research and development expenses for the three months ended March 31, 2023, amounted to $2 million, up from $1.2 million in the same period in 2022, primarily due to the launch of NanoAb development[80] - As of March 31, 2023, the company had cash and cash equivalents of $10.9 million, a decrease from $15.5 million as of March 31, 2022[90] - The company raised gross proceeds of approximately $8 million from a public follow-on offering completed in December 2022[84] - The company expects to incur additional losses due to ongoing research and development activities and may need to secure additional funding to support these initiatives[79] - General and administrative expenses for the three months ended March 31, 2023, were $1.2 million, down from $1.4 million in the same period in 2022[88] - The company has an accumulated deficit of $119.3 million as of March 31, 2023[93] - The company plans to continue funding operations through public and private equity offerings, grants, and loans, but there is no assurance that additional funding will be available on acceptable terms[86] - The company anticipates that a significant portion of future research and development expenses will be directed towards clinical development projects, which are inherently unpredictable[81] Strategic Partnerships and Leadership - The company is actively engaged in identifying and evaluating partnership opportunities within the pharmaceutical industry to enhance its market presence[73] - BiondVax's leadership team has extensive experience in the biotech and pharmaceutical sectors, which is expected to drive the company's strategic initiatives[76]

Financial Performance - For the year ended December 31, 2022, the net loss was $5.8 million, a decrease from the net loss of $8.2 million for the year ended December 31, 2021, reflecting improved financial performance [313]. - The accumulated deficit amounted to $115.8 million as of December 31, 2022, indicating ongoing financial challenges [318]. - The company expects to continue incurring operating losses and may need to raise additional funds to support its research and development activities [303]. Research and Development - Research and development expenses increased to $5.7 million for the year ended December 31, 2022, compared to $3.2 million for the year ended December 31, 2021, primarily due to increased salaries and expenses related to the COVID-19 NanoAb project [304]. - The company signed a five-year Research Collaboration Agreement with MPG and UMG for the discovery and development of NanoAbs for various diseases, which are expected to address large and growing markets [300]. - The company anticipates that a significant portion of future research and development expenses will be related to its clinical development projects, which are inherently unpredictable [305]. Cash and Funding - As of December 31, 2022, the company had cash and cash equivalents of $14 million, down from $17.3 million as of December 31, 2021 [314]. - The company raised gross proceeds of approximately $8 million from a public follow-on offering completed in December 2022 [308]. - The Company closed an underwritten offering selling 1,600,000 units, receiving a net sum of $7.3 million after issuance expenses [321]. - Each unit was sold at a combined purchase price of $5.00, with pre-funded units priced at $4.999 [321]. - The company has received $5.8 million in IIA grants and €24 million ($25.6 million) in EIB loans since its inception, which have supported its operations [311]. Clinical Trials - The company has executed eight clinical trials, including a phase 3 trial with 12,400 participants for its previous lead drug candidate, M-001, which is no longer under development [297]. Asset Valuation - No impairment indicators for long-lived assets were identified during the years ended December 31, 2022 and 2021 [324]. - The fair value of financial instruments is measured based on a three-tiered hierarchy prioritizing inputs used in valuation methodologies [325]. - The Company is not required to provide market risk disclosures as it qualifies as a smaller reporting company [326].

Financial Data and Key Metrics Changes - As of the end of 2021, the company held $17.4 million in cash, which is expected to be sufficient to reach the first in-human studies for the COVID-19 NanoAbs [12][37] - The company has agreed on terms for restructuring its outstanding debt to the European Investment Bank, extending the maturity date to December 31, 2027, which will provide a runway for development [10][11] Business Line Data and Key Metrics Changes - The company is progressing with the COVID-19 NanoAb development, focusing on technology transfer and scale-up of the manufacturing process [5][6] - A recent collaboration with the Max Planck Institute and University Medical Center Göttingen will expand the NanoAb platform to include nine additional NanoAbs targeting diseases with unmet medical needs [8][9] Market Data and Key Metrics Changes - The market for COVID-19 treatments is expected to grow, with estimates indicating it has already surpassed $2 billion [33] - The company is targeting therapeutic areas such as asthma, psoriasis, psoriatic arthritis, and macular degeneration, which have a compound annual growth rate (CAGR) of 8% to 12% [31][33] Company Strategy and Development Direction - The company aims to develop a self-administered inhaled COVID-19 NanoAb that is expected to have a lower adverse events profile and be more affordable than current therapies [30][31] - The strategy includes a focus on well-validated targets for existing monoclonal antibody treatments to reduce risk [43] Management's Comments on Operating Environment and Future Outlook - Management believes that COVID-19 will continue to circulate, necessitating a range of therapeutic options alongside vaccines [28][29] - The company anticipates initiating clinical trials for the COVID-19 NanoAb in 2023, with potential market entry depending on the pandemic situation [35][51] Other Important Information - The company has strengthened its R&D capabilities by hiring top talent and enhancing its Board with experienced individuals from the pharmaceutical industry [13][15] - The manufacturing site is designed to meet FDA and EMA standards, allowing for rapid drug development and lower risk of delays [36] Q&A Session Summary Question: What are the advantages of NanoAbs over similar therapies in general? - NanoAbs can be developed to be more potent and stable, allowing for lower concentrations and potentially fewer side effects [39][40] Question: What are the risks of using NanoAbs? - Risks include the potential for immune responses and on-target risks, but NanoAbs may be less immunogenic due to their compact structure [41][42] Question: What do you estimate will be the retail cost per unit of the COVID treatment relative to other COVID therapies? - The company expects to price its treatment substantially lower than existing therapies, which can cost around $2,000 per dose [44][45] Question: What are the upcoming catalysts? - Key catalysts include finalizing the agreement with the EIB and conducting proof-of-concept studies for the inhalation route of administration [46][47] Question: When do you expect the first COVID-19 drug to be in the market? - The company anticipates a worst-case scenario of filing for marketing approval by 2026, depending on the pandemic situation [51][52] Question: Are there any other companies developing NanoAbs? - Other companies exist, such as Ablynx, but the company believes its capabilities and partnerships provide a competitive edge [53][54] Question: How does the company plan to address COVID mutations? - The company plans to develop NanoAbs that can neutralize all variants of concern, adapting its approach similar to influenza vaccine strategies [56][57]

Financial Position - The company has incurred an accumulated deficit of $117.3 million as of December 31, 2021, and expects to experience negative cash flow for the foreseeable future [40]. - The company had approximately $17.4 million in cash and cash equivalents and working capital of $15.4 million as of December 31, 2021, which is expected to fund operations for at least the next 12 months [41]. - The company may require substantial additional financing to achieve its goals, and failure to obtain necessary capital could delay or terminate product development efforts [41]. - The company may seek additional capital through private and public equity offerings, debt financings, and strategic partnerships, which could lead to dilution of existing shareholders [53]. - The company’s balance sheet is expected to primarily consist of cash and cash equivalents, impacting its PFIC status based on asset composition [197]. Product Development and Pipeline - The company does not currently have any product candidates that generate revenue and does not expect to become profitable in the near future [38]. - The company’s business strategy is evolving from being a one-product company focused on M-001 to building a diversified pipeline of assets [45]. - The company has a pipeline of products aimed at preventing and treating infectious diseases, with various routes of drug delivery and at different stages of clinical development [50]. - The company has entered into a licensing and collaboration arrangement for its Covid-19 NanoAbs program, although it currently has no product candidates in clinical trials or on the market [54]. - The company’s NanoAbs program is at an earlier stage of clinical development compared to M-001, and its success is uncertain [45]. Regulatory and Compliance Challenges - Regulatory approval processes for current and future product candidates are extensive and can take many years, with no guarantee of success [63]. - Ongoing regulatory requirements will apply even after obtaining approval for product candidates, and failure to comply could result in loss of approvals [66]. - The company faces significant regulatory challenges that could hinder the approval and commercialization of current and future product candidates, potentially impacting financial performance [104]. - The FDA may not accept data from clinical trials conducted outside the U.S., potentially requiring additional costly trials [77]. - The company is subject to extensive government regulations that increase the cost and risk associated with research, development, and sales of pharmaceutical products [105]. Market and Competitive Landscape - The company faces significant competition in the biopharmaceutical market, which may impact its marketing and sales efforts [39]. - Current and future product candidates may encounter competition sooner than expected, particularly from biosimilar products, impacting market exclusivity [68]. - The twelve-year exclusivity period for biological products may not be granted or could be shortened, leading to earlier generic competition [69]. - The company operates in a highly competitive environment, facing challenges from larger pharmaceutical firms with greater resources and experience [117]. Risks and Liabilities - The company may face product liability lawsuits, which could result in substantial financial liabilities and affect commercialization efforts [123]. - Serious side effects reported during clinical trials could lead to regulatory refusal of product approvals or revocation of existing authorizations [86]. - The company is exposed to risks associated with insider trading allegations, which could negatively impact its reputation and stock price [127]. - Employee misconduct or fraud could lead to significant regulatory sanctions and reputational harm, impacting business operations [126]. - The company may struggle with market acceptance and sales of product candidates if coverage and reimbursement policies are not favorable, which could affect profitability [95]. Intellectual Property Concerns - The company faces significant risks related to intellectual property, including potential challenges to patent rights that could limit competitive advantage [157]. - The ability to enforce patent rights may be hampered by financial resources, leading to potential loss of exclusivity and market position [165]. - Litigation related to intellectual property claims could result in substantial costs and divert management's attention from core business activities [169]. - The company may need to initiate costly litigation to protect its intellectual property rights, which could strain resources and impact financial stability [164]. Operational and Strategic Considerations - The company must establish and maintain strategic collaborations to successfully commercialize its pipeline candidates, as its long-term viability depends on these partnerships [59]. - The company relies on third parties for clinical trials and product development, which may lead to delays if these parties do not perform satisfactorily [145]. - The company must attract and retain qualified personnel to effectively operate its business, which may be challenging due to limited financial resources [113]. - The company may face difficulties in managing growth, which could adversely affect its business and financial condition [128]. Economic and Market Conditions - Future economic conditions, influenced by the COVID-19 pandemic, may disrupt global financial markets and affect the company's liquidity and financial position [91]. - The ongoing COVID-19 pandemic has created uncertainty regarding the company's ability to identify and develop product candidates, which may adversely affect future revenues [90]. - The market price for the ADSs has been and is likely to remain highly volatile, influenced by factors such as clinical trial authorizations and regulatory approvals [209]. - The trading prices for securities of other biopharmaceutical companies have been highly volatile, particularly due to the COVID-19 pandemic [212]. Corporate Governance and Shareholder Issues - Angels Investments in High Tech Ltd. holds approximately 22.7% of the voting power of the outstanding ADSs, allowing it to significantly influence corporate actions [195]. - The company has not paid any cash dividends on the ADSs since inception and does not anticipate paying any in the foreseeable future [203]. - Holders of ADSs do not have the same rights as ordinary shareholders and may face limitations in exercising voting rights [206]. - The company’s articles of association stagger the election of directors, which may hinder a potential acquirer from easily changing the board [189].

Clinical Trial Results and Product Development - The company's sole product candidate, M-001, failed to meet primary and secondary efficacy endpoints in its pivotal Phase 3 clinical trial, which has had a material adverse effect on its operations and future prospects [32]. - The pivotal Phase 3 clinical trial for the M-001 product candidate failed to meet both primary and secondary efficacy endpoints, adversely affecting commercialization efforts [43]. - The M-001 product candidate failed to meet both primary and secondary efficacy endpoints in a pivotal Phase 3 clinical trial after successful results in earlier stages [78]. - The company is no longer actively developing M-001 after the Phase 3 trial results, although it may consider returning to its development in the future [213]. - The pivotal Phase 3 clinical trial for M-001 involved over 12,463 participants across two cohorts, but failed to meet primary and secondary efficacy endpoints [220]. Financial Condition and Capital Requirements - The company requires substantial additional financing to achieve its goals, and failure to secure this capital could delay or terminate product development efforts [33]. - The company will require substantial additional financing to continue operations and execute its business plan [47]. - The company has incurred losses since its inception, with an accumulated deficit of $101 million as of December 31, 2020 [47]. - As of December 31, 2020, the company had approximately $2.9 million in cash and cash equivalents and negative working capital of $16.6 million [47]. - Recent disruptions in financial markets may impact the company's ability to raise capital on acceptable terms [119]. Strategic Alternatives and Business Operations - The company has no current product candidates and is exploring strategic alternatives to maximize shareholder value, including potential licensing, divestiture, or acquisition of assets [34]. - The exploration of strategic alternatives may incur substantial expenses and could disrupt business operations, diverting management's attention from core activities [35]. - The company may be forced to liquidate or wind down operations if it cannot identify or execute on strategic alternatives within a reasonable timeframe [34]. - The company has no clear business strategy following the negative trial results and may face significant additional losses before establishing a new strategy [43]. - The company is in a developmental stage with no approved product candidates, making it difficult to assess future viability and requiring successful execution of various strategic objectives [105]. Regulatory and Compliance Challenges - The regulatory approval process for any Company product candidate is expensive and can take many years, with a high rate of attrition in clinical trials [60]. - The FDA or comparable foreign regulatory authorities can delay or deny approval for various reasons, including safety concerns and disagreements over clinical trial designs [61]. - Even after receiving regulatory approval, Company product candidates remain subject to ongoing regulatory requirements, which could impact commercial viability [62]. - The approval process may be impacted by changes in legislation or regulatory policies, which could further delay commercialization [61]. - The company is subject to extensive government regulations, including those from the FDA and EMA, which significantly increase the cost and risk of product development and sales [97]. Market and Competitive Risks - The company faces significant risks related to its dependence on strategic partnerships for the development and commercialization of any product candidates, with no current partnerships established [38]. - The company may face competition from biosimilar products sooner than anticipated, as the Biologics Price Competition and Innovation Act allows for abbreviated approval pathways [64]. - The extent of market acceptance for the company's product candidates will depend on competitive factors, which are largely beyond its control [110]. - Competition from larger pharmaceutical companies and research institutions poses a significant risk, as they may develop and commercialize products faster than the company [108]. - The company faces potential adverse events from product candidates that could negatively impact sales and financial results [112]. Intellectual Property and Legal Risks - The company faces risks related to intellectual property rights, including potential challenges to patents that could diminish competitive position [140]. - The company may need to engage in costly litigation to protect its intellectual property rights and could face claims of infringement from others [149]. - Noncompliance with patent maintenance requirements could lead to loss of patent rights, allowing competitors to enter the market [148]. - There is a risk of being ordered to cease operations or redesign products due to third-party patent infringement claims, which could require significant time and financial resources [151]. - The company may incur substantial damages, including treble damages and attorney fees, if found to infringe on third-party patents [152]. Operational and Management Challenges - The company faces challenges in attracting and retaining qualified personnel due to its limited financial resources and negative trial results [45]. - Difficulties in managing growth could adversely affect business operations and financial condition [116]. - The company depends on third parties for clinical trials, which may not perform satisfactorily, potentially delaying product development [132]. - Reliance on third-party manufacturers increases the risk of insufficient product supply, which could impair commercialization efforts [135]. - The company must comply with cGMP regulations, and failure to do so could result in significant sanctions and affect product supplies [136]. Shareholder and Market Considerations - The company's share price significantly declined following the announcement of the unfavorable clinical trial results, which may expose it to potential securities class action litigation [41]. - The company has not paid dividends on its Ordinary Shares and does not intend to do so in the foreseeable future, limiting potential benefits for investors [201]. - Future equity offerings may dilute existing shareholders' ownership and influence over company matters [205]. - Holders of ADSs may face limitations on their voting rights and may not receive timely voting materials, potentially affecting their ability to influence shareholder decisions [203]. - Substantial future sales of ADSs may cause the market price to decline, impacting existing shareholders [199]. Environmental and Regulatory Compliance - The company is subject to extensive environmental, health, and safety regulations, which could lead to significant costs and liabilities [120]. - Non-compliance with healthcare regulations could result in severe penalties, including fines and exclusion from government programs, adversely affecting the company's financial condition [98]. - The company must navigate complex relationships with healthcare providers and third-party payors, which are subject to anti-kickback and fraud laws that could impact business operations [99]. - The company must comply with the Innovation Law and related regulations due to the receipt of IIA grants, which may restrict the transfer of know-how outside of Israel [178]. - The company may be subject to financial sanctions and mandatory repayment of grants if it fails to comply with the requirements under the Innovation Law [180]. Economic and Political Risks - Political, economic, and military instability in Israel could adversely affect the company's operations and ability to raise capital [162]. - Obligations for military service among Israeli citizens may disrupt the company's operations, potentially affecting its financial condition [163]. - Currency fluctuations may adversely affect the company's results of operations, as some expenses are incurred in currencies other than the U.S. Dollar [176]. - The company is subject to various taxes and compliance obligations in Israel, with potential changes in tax laws increasing overall tax liabilities [169]. - The controlling shareholder, Angels Investments in High Tech Ltd., owned 37.1% of the voting power of the company's outstanding Ordinary Shares as of December 31, 2020, significantly influencing corporate decisions [181].